{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T11:51:29Z","timestamp":1793101889803,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["813545"],"award-info":[{"award-number":["813545"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-114909RB-I00"],"award-info":[{"award-number":["PID2020-114909RB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007211","name":"Vasculitis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2021 SGR 01561"],"award-info":[{"award-number":["2021 SGR 01561"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ard.2025.02.008","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T08:27:56Z","timestamp":1741681676000},"page":"1387-1400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The IL-6 axis in vascular inflammation: effects of IL-6 receptor blockade on vascular lesions from patients with giant-cell arteritis"],"prefix":"10.1016","volume":"84","author":[{"given":"Marc","family":"Corbera-Bellalta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Kamberovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3308-5787","authenticated-orcid":false,"given":"Roser","family":"Alba-Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Planas-Rigol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3179-597X","authenticated-orcid":false,"given":"Sergio","family":"Prieto-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Farran-Centelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Tob\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jord\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Esp\u00edgol-Frigol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0938","authenticated-orcid":false,"given":"Maria C.","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ard.2025.02.008_bib0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41572-021-00327-5","article-title":"Large-vessel vasculitis","volume":"7","author":"Pugh","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.ard.2025.02.008_bib0002","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MD.0000000000000033","article-title":"Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients","volume":"93","author":"Alba","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"10031","key":"10.1016\/j.ard.2025.02.008_bib0003","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ard.2025.02.008_bib0004","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ard.2025.02.008_bib0005","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.008_bib0006","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.02.008_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002923","article-title":"Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis","volume":"9","author":"Matza","year":"2023","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.ard.2025.02.008_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103716","article-title":"Targeting interleukin-6 pathways in giant cell arteritis management: a narrative review of evidence","volume":"24","author":"Samson","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.ard.2025.02.008_bib0009","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S2665-9913(21)00038-2","article-title":"Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial","volume":"3","author":"Stone","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2025.02.008_bib0010","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/j.2326-5205.1989.tb00020.x","article-title":"Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment","volume":"32","author":"Cid","year":"1989","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ard.2025.02.008_bib0011","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-121-7-199410010-00003","article-title":"Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis","volume":"121","author":"Weyand","year":"1994","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ard.2025.02.008_bib0012","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/annrheumdis-2015-208371","article-title":"Blocking interferon \u03b3 reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis","volume":"75","author":"Corbera-Bellalta","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2025.02.008_bib0013","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/rheumatology\/ker163","article-title":"Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis\u2013a prospective longitudinal study","volume":"50","author":"Visvanathan","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.ard.2025.02.008_bib0014","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1136\/annrheumdis-2012-201836","article-title":"Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis","volume":"72","author":"Esp\u00edgol-Frigol\u00e9","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2025.02.008_bib0015","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.it.2012.07.003","article-title":"Interleukin-6: from an inflammatory marker to a target for inflammatory diseases","volume":"33","author":"Rincon","year":"2012","journal-title":"Trends Immunol"},{"issue":"4","key":"10.1016\/j.ard.2025.02.008_bib0016","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2019.03.027","article-title":"Pleiotropy and specificity: insights from the interleukin 6 family of cytokines","volume":"50","author":"Murakami","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.ard.2025.02.008_bib0017","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.ard.2025.02.008_bib0018","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2025.02.008_bib0019","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.ard.2025.02.008_bib0020","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/ATVBAHA.110.207464","article-title":"Suppressors of cytokine signaling (SOCS) proteins and JAK\/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3","volume":"31","author":"Tamiya","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ard.2025.02.008_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1255533","article-title":"Interleukin 6: at the interface of human health and disease","volume":"14","author":"Grebenciucova","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2025.02.008_bib0022","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cytogfr.2023.12.007","article-title":"Navigating IL-6: from molecular mechanisms to therapeutic breakthroughs","volume":"76","author":"Swaroop","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"10.1016\/j.ard.2025.02.008_bib0023","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/rheumatology\/29.6.456","article-title":"Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis","volume":"29","author":"Dasgupta","year":"1990","journal-title":"Br J Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.02.008_bib0024","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/art.1780360913","article-title":"Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis","volume":"36","author":"Roche","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.02.008_bib0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art1.10161","article-title":"A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis","volume":"47","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ard.2025.02.008_bib0026","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/acr.20043","article-title":"Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis","volume":"62","author":"Garc\u00eda-Mart\u00ednez","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.ard.2025.02.008_bib0027","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1172\/JCI117428","article-title":"Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease","volume":"94","author":"Wagner","year":"1994","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ard.2025.02.008_bib0028","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/rheumatology\/keh058","article-title":"Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis","volume":"43","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.ard.2025.02.008_bib0029","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/art.40876","article-title":"Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab","volume":"71","author":"Stone","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.02.008_bib0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejim.2024.06.013","article-title":"Effectiveness of tocilizumab in aortitis and aneurysms associated with giant cell arteritis","volume":"129","author":"Mart\u00edn-Guti\u00e9rrez","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.ard.2025.02.008_bib0031","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/rheumatology\/kead215","article-title":"Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study","volume":"63","author":"Muratore","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ard.2025.02.008_bib0032","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/key015","article-title":"Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis","volume":"57","author":"Reichenbach","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.ard.2025.02.008_bib0033","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1093\/rheumatology\/keaa894","article-title":"Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis","volume":"60","author":"Quinn","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.ard.2025.02.008_bib0034","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1093\/rheumatology\/keab332","article-title":"Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study","volume":"60","author":"Sch\u00f6nau","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.02.008_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152174","article-title":"Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: a single-centre prospective study","volume":"59","author":"Tomelleri","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.02.008_bib0036","first-page":"keae378","article-title":"Magnetic resonance imaging to monitor disease activity in giant cell arteritis treated with ultra-short glucocorticoids and tocilizumab","author":"Christ","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.ard.2025.02.008_bib0037","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/acr.21750","article-title":"Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica","volume":"64","author":"Unizony","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.ard.2025.02.008_bib0038","first-page":"985","article-title":"Progression of large-vessel giant cell arteritis despite tocilizumab treatment","volume":"41","author":"Elfishawi","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.02.008_bib0039","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/rheumatology\/kex333","article-title":"Discrepancies between vascular and systemic inflammation in large vessel vasculitis: an important problem revisited","volume":"57","author":"Keser","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ard.2025.02.008_bib0040","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/annrheumdis-2012-202883","article-title":"Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis","volume":"73","author":"Corbera-Bellalta","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2025.02.008_bib0041","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1136\/ard.2007.070805","article-title":"Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis","volume":"67","author":"Lozano","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.02.008_bib0042","article-title":"Preparation of endothelial cells","author":"Kleinman","year":"2001","journal-title":"Curr Protoc Cell Biol"},{"issue":"9","key":"10.1016\/j.ard.2025.02.008_bib0043","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1136\/annrheumdis-2016-210792","article-title":"Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis","volume":"76","author":"Planas-Rigol","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"D1","key":"10.1016\/j.ard.2025.02.008_bib0044","doi-asserted-by":"crossref","first-page":"D1016","DOI":"10.1093\/nar\/gkae1080","article-title":"Harmonizome 3.0: integrated knowledge about genes and proteins from diverse multi-omics resources","volume":"53","author":"Diamant","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.1016\/j.ard.2025.02.008_bib0045","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/annrheumdis-2015-207846","article-title":"MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis","volume":"75","author":"Croci","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.02.008_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103739","article-title":"Current state of epigenetics in giant cell arteritis: focus on microRNA dysregulation","volume":"24","author":"Bolha","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ard.2025.02.008_bib0047","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3389\/fimmu.2016.00479","article-title":"Expanding diversity in molecular structures and functions of the IL-6\/IL-12 heterodimeric cytokine family","volume":"7","author":"Hasegawa","year":"2016","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.008_bib0048","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/rheumatology\/kex334","article-title":"Increased expression of interleukin-22 in patients with giant cell arteritis","volume":"57","author":"Zerbini","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.02.008_bib0049","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3389\/fimmu.2018.00809","article-title":"Expression and function of IL12\/23 related cytokine subunits (p35, p40, and p19) in giant-cell arteritis lesions: contribution of p40 to Th1- and Th17-mediated inflammatory pathways","volume":"9","author":"Esp\u00edgol-Frigol\u00e9","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ard.2025.02.008_bib0050","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bbrc.2004.12.074","article-title":"Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts","volume":"327","author":"Ramana","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.ard.2025.02.008_bib0051","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/annrheumdis-2021-220873","article-title":"Blocking GM-CSF receptor \u03b1 with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis","volume":"81","author":"Corbera-Bellalta","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2025.02.008_bib0052","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2016-210070","article-title":"An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy","volume":"76","author":"Miyabe","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.02.008_bib0053","doi-asserted-by":"crossref","first-page":"e1332","DOI":"10.1002\/cti2.1332","article-title":"Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis","volume":"10","author":"Samson","year":"2021","journal-title":"Clin Transl Immunology"},{"issue":"6","key":"10.1016\/j.ard.2025.02.008_bib0054","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/ni938","article-title":"IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages","volume":"4","author":"Yasukawa","year":"2003","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1016\/j.ard.2025.02.008_bib0055","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamacardio.2018.2287","article-title":"Association of interleukin 6 receptor variant with cardiovascular disease effects of interleukin 6 receptor blocking therapy: a phenome-wide association study","volume":"3","author":"Cai","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ard.2025.02.008_bib0056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2023.03.002","article-title":"Monocyte chemokine receptors as therapeutic targets in cardiovascular diseases","volume":"256-257","author":"Germano","year":"2023","journal-title":"Immunol Lett"},{"issue":"11","key":"10.1016\/j.ard.2025.02.008_bib0057","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/rheumatology\/kel128","article-title":"Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis","volume":"45","author":"Cid","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ard.2025.02.008_bib0058","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semcdb.2008.06.004","article-title":"Ups and downs: the STAT1:STAT3 seesaw of interferon and gp130 receptor signalling","volume":"19","author":"Regis","year":"2008","journal-title":"Semin Cell Dev Biol"},{"issue":"20","key":"10.1016\/j.ard.2025.02.008_bib0059","doi-asserted-by":"crossref","first-page":"14111","DOI":"10.1074\/jbc.M511797200","article-title":"Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation","volume":"281","author":"Ho","year":"2006","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.ard.2025.02.008_bib0060","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1172\/JCI119477","article-title":"Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras","volume":"99","author":"Brack","year":"1997","journal-title":"J Clin Invest"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725002365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725002365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T04:13:48Z","timestamp":1778386428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725002365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0003496725002365"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.02.008","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The IL-6 axis in vascular inflammation: effects of IL-6 receptor blockade on vascular lesions from patients with giant-cell arteritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}